No Breast Cancer Survival Benefit for Extending Adjuvant Letrozole Therapy to 5 Years

Share this content:
Extending adjuvant letrozole from 2.5 to 5 years does not improve disease-free survival or overall survival outcomes among women with breast cancer.
Extending adjuvant letrozole from 2.5 to 5 years does not improve disease-free survival or overall survival outcomes among women with breast cancer.

Extending adjuvant letrozole from 2.5 to 5 years does not improve disease-free survival or overall survival outcomes among women with breast cancer, but might be associated with reduced risk of a second primary breast tumor, according to findings from the phase 3 IDEAL Trial, presented at the 2016 San Antonio Breast Cancer Symposium.

“There were no significant differences in disease-related outcomes,” reported Erik J. Blok, MD, of the department of medical oncology, Leiden University Medical Center in Netherlands. “There is no benefit of extending AI-based adjuvant therapy longer than 2.5 years.”

There was a high frequency of adverse events, with 70% of patients in each study arm experiencing toxicities. The most common toxicities were arthralgia (14%), hot flashes (12%), and osteoporosis (10%).

Adjuvant endocrine therapy with aromatase inhibition (AI) or tamoxifen is the mainstay of breast cancer treatment. AI appears to be superior to tamoxifen in the first 5 years, whether delivered sequentially or up-front, Dr Blok noted.

The new study was undertaken to analyze whether adjuvant letrozole should be extended to 2.5 years or 5 years.

Patients were enrolled at 74 hospitals across the Netherlands between 2007 and 2011. A total of 1821 eligible patients were included in the study. Median follow-up was 6.5 years, and 1338 were available for secondary analysis after disease progression events in 483 patients.

Toxicities “had an effect on compliance,” Dr Blok noted. A total of 241 patients in the 2.5-year study arm stopped treatment early, of whom 179 (74%) stopped because of adverse events and drug refusal. In the 5-year group, 385 patients stopped early, of which 254 (66%) stopped because of adverse events and drug refusal.

RELATED: Promising Options Emerging for Treating Metastatic ER+ Breast Cancer

In subsequent competing risk modeling, the research team did identify a significant difference in the prevention of second primary breast tumors, with a hazard ratio (HR) of 0.37, a “small absolute risk reduction of 1% at 5 years,” Dr Blok noted. “This was similar to findings in healthy women.”

Prevention of new primary breast tumors should be explored as a possible therapy goal for adjuvant therapy, he suggested.

Reference

  1. Blok EJ, van de Velde CJH, Meershoek-Klein Kranenbarg EM, et al. Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006-05). Paper presented at: 39th San Antonio Breast Cancer Symposium; December 2016; San Antonio, TX.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs